Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

3.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 650
Open 3.760
Bid (Size) 3.210 (1)
Ask (Size) 3.870 (5)
Prev. Close 3.760
Today's Range 3.760 - 3.760
52wk Range 1.630 - 8.830
Shares Outstanding 98,384,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Via Benzinga
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga

Performance

YTD
+1.90%
+1.90%
1 Month
+6.82%
+6.82%
3 Month
-45.27%
-45.27%
6 Month
+1.08%
+1.08%
1 Year
-24.50%
-24.50%

More News

Read More
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Via Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
From Fate Therapeutics, Inc.
Via GlobeNewswire
Where Fate Therapeutics Stands With Analysts
Via Benzinga
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Via Benzinga
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Recap: Fate Therapeutics Q4 Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 26, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.